168 related articles for article (PubMed ID: 12352271)
1. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
3. Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients.
Laghrissi-Thode F; Pollock BG; Miller MC; Mulsant BH; Altieri L; Finkel MS
Psychopharmacol Bull; 1995; 31(4):659-63. PubMed ID: 8851637
[TBL] [Abstract][Full Text] [Related]
4. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression.
Murphy GM; Pollock BG; Kirshner MA; Pascoe N; Cheuk W; Mulsant BH; Reynolds CF
Neuropsychopharmacology; 2001 Nov; 25(5):737-43. PubMed ID: 11682257
[TBL] [Abstract][Full Text] [Related]
6. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients.
Mamo DC; Sweet RA; Mulsant BH; Pollock BG; Miller MD; Stack JA; Begley AE; Reynolds CF
Am J Geriatr Psychiatry; 2000; 8(3):226-31. PubMed ID: 10910421
[TBL] [Abstract][Full Text] [Related]
7. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.
Bertilsson L; Aberg-Wistedt A; Gustafsson LL; Nordin C
Ther Drug Monit; 1985; 7(4):478-80. PubMed ID: 4082245
[No Abstract] [Full Text] [Related]
8. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
9. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
10. Lack of desipramine toxicity with citalopram.
Ashton AK
J Clin Psychiatry; 2000 Feb; 61(2):144. PubMed ID: 10732663
[No Abstract] [Full Text] [Related]
11. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome.
Mulsant BH; Pollock BG; Nebes RD; Miller MD; Little JT; Stack J; Houck PR; Bensasi S; Mazumdar S; Reynolds CF
J Clin Psychiatry; 1999; 60 Suppl 20():16-20. PubMed ID: 10513853
[TBL] [Abstract][Full Text] [Related]
12. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
13. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
15. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline.
Pollock BG; Mulsant BH; Nebes R; Kirshner MA; Begley AE; Mazumdar S; Reynolds CF
Am J Psychiatry; 1998 Aug; 155(8):1110-2. PubMed ID: 9699704
[TBL] [Abstract][Full Text] [Related]
16. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.
Nelson JC; Kennedy JS; Pollock BG; Laghrissi-Thode F; Narayan M; Nobler MS; Robin DW; Gergel I; McCafferty J; Roose S
Am J Psychiatry; 1999 Jul; 156(7):1024-8. PubMed ID: 10401446
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.
Nordin C; Siwers B; Benitez J; Bertilsson L
Br J Clin Pharmacol; 1985 Jun; 19(6):832-5. PubMed ID: 4027124
[TBL] [Abstract][Full Text] [Related]
18. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
19. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years.
Walters G; Reynolds CF; Mulsant BH; Pollock BG
J Clin Psychiatry; 1999; 60 Suppl 20():21-5. PubMed ID: 10513854
[TBL] [Abstract][Full Text] [Related]
20. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
